JAGSNPHARM

Jagsonpal Pharmaceuticals Ltd.

NSE: JAGSNPHARM

BSE: 507789

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

230.65+5.2 (+2.30%)

13 Aug, 1:59 PM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

93.7 / 100

Value Score

40.5 / 100

Price Momentum Score

66.8 / 100

QVM Score

83.2 / 100

Key Metrics

Market Cap

1486.50

P/E (TTM)

32.69

P/B

5.38

P/S (TTM)

5.06

EV/EBITDA

22.72

CAPE (5Y)

44.21

ROE (TTM)

16.69

ROCE (TTM)

18.23

ROA (TTM)

14.48

Avg 3Y ROE

18.53

Earnings 3Y CAGR

12.03

Sales 3Y CAGR

7.54

Sales 5Y CAGR

6.32

Debt/Equity

0.03

Consensus TP

Strong Buy %

Promoter Holding

69.05

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Jagsonpal Pharmaceuticals Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

High and improving operating margin

The company reported strong operating margin of 17.65% for 12-month ended 30 Jun 2026 and operating margin improved by 151 bps from 1 year ago

What is Operating profit margin?

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.03 as on 30 Jun 2026 and Debt to Equity decreased marginally by 0.01 in the last 1 year

What is Debt to Equity?

Consistently pays dividend

The company has not missed dividend payments once in the last 3 financial years

What is Dividend streak?

Company is net cash

The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet

What is Net Debt ?

Negative

Expensive and at a premium to industry median P/E

PE TTM of 32.69 indicates that the stock is expensive on a standalone basis and is at a 10.44% premium to industry median P/E

What is P/E Ratio?

Median: 29.6

Value 32.69

0.33286.35

Low revenue growth and lower than median growth of industry

The company delivered moderate revenue growth of 3.87% for 12-month ended 30 Jun 2026 and the growth was 7.71 percentage points lower than median growth of industry

What is Sales growth (1Y)?

Median: 11.58

Value 3.87

-42.894040.18

Low EPS growth and lower than median growth of industry

The company delivered moderate EPS growth of -25.37% for 12-month ended 30 Jun 2026 and the growth was 35.12 percentage points lower than median growth of industry

What is EPS growth (1Y)?

Neutral

High ROE but declining trend

The company reported strong ROE of 16.69% for 12-month ended 30 Jun 2026 but ROE declined by -922 bps from 1 year ago

What is ROE (FY)?

Company's earnings are of moderate quality

Earnings quality score of 64.6 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

64.6 / 100

Moderate dividend yield

The company has a moderate dividend yield of 1.77%

What is Dividend yield?

Financial Snapshot

See detailed analysis

Multi-year trends for Jagsonpal Pharmaceuticals Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Jagsonpal Pharmaceuticals Ltd. Shareholding Pattern

Quarterly breakdown of Jagsonpal Pharmaceuticals Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Promoter	70.34	70.34	70.34	70.34	70.34	70.34	70.34	70.34	68.71	68.71	68.72	68.71	68.71	68.71	68.71	68.48	68.09	68.04	67.97	67.81	67.78	67.65	67.54	67.39	67.89	69.05
Indian Promoter	70.34	70.34	70.34	70.34	70.34	70.34	70.34	70.34	68.71	68.71	68.72	68.71	24.99	24.99	24.99	24.90	24.76	24.74	24.72	24.66	24.65	24.60	24.56	24.51	25.12	25.55
Foreign Promoter	-	-	-	-	-	-	-	-	-	-	-	-	43.73	43.73	43.73	43.58	43.33	43.30	43.25	43.15	43.13	43.05	42.98	42.88	42.77	43.50
Institutions	0.01	0.00	0.00	0.00	0.00	0.00	0.12	0.20	0.67	0.68	0.41	0.88	0.93	1.20	1.21	1.35	1.58	1.95	2.41	2.10	2.10	2.23	2.21	2.27	2.66	2.92
Mutual Funds / UTI	-	-	-	-	-	-	-	-	-	-	0.00	-	-	-	-	-	-	-	0.11	-	-	-	-	-	-	-
FI/Bank/Insurance	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Govt	-	-	-	-	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FII	0.00	0.00	0.00	0.00	0.00	0.00	0.11	0.20	0.00	0.00	0.13	0.00	0.00	0.37	0.38	0.53	0.73	1.10	2.30	2.10	2.10	2.17	2.12	2.12	2.44	2.30
Other Institutions	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.20	0.66	0.67	0.28	0.88	0.92	0.82	0.82	0.82	0.84	0.85	0.00	0.00	0.00	0.05	0.08	0.15	0.22	0.62
Non-Institution	29.66	29.66	29.66	29.66	29.65	29.65	29.54	29.46	30.61	30.61	30.85	30.41	30.36	30.08	30.08	30.17	30.33	30.01	29.62	30.08	30.11	30.12	30.25	30.34	29.45	28.03
Bodies Corporate	1.69	1.67	1.80	0.85	1.12	0.77	3.57	3.07	5.82	3.85	2.49	3.94	2.84	2.91	2.65	2.78	3.54	3.44	2.99	2.98	2.63	2.54	2.49	2.49	2.51	2.61
Others (incl. Retail) No. of shareholders	27.97 8,978	27.99 9,574	27.86 10,265	28.81 12,018	28.53 12,479	28.88 14,537	25.97 14,261	26.39 19,932	24.79 17,014	26.76 16,092	28.36 14,848	26.47 14,435	27.52 13,986	27.17 13,675	27.43 15,945	27.39 15,687	26.79 16,181	26.57 15,638	26.63 15,514	27.10 18,328	27.48 20,953	27.58 22,765	27.76 24,512	27.85 24,763	26.94 26,120	25.42 24,040

Holdings and Presence

Indices and prominent investors with a stake in this stock.

Index Presence

Jagsonpal Pharmaceuticals Ltd. is not part of any tracked index.

Prominent Investor Holdings

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Jagsonpal Pharmaceuticals Ltd. shares as reported to NSE and BSE.

Name	Month	Transaction	Holding % pre transaction	Average price	Qty.	Transaction value
Rajpal Singh Kochhar for and on behalf of Aresko Progressive Private Limited acting in capacity as a trustee of the Aresko Progressive Trust; and as the representative partner of J&P Investments Partnership Promoter Group	June-2022	Off Market (Disposal) 29th Jun 2022	64.10 %	₹ 235.00	1.15 cr	₹ 269.20 cr
Rajpal Singh Kochhar for and on behalf of Aresko Progressive Private Limited acting in capacity as a trustee of the Aresko Progressive Trust; and as the representative partner of J&P Investments Partnership Promoter Group	February-2022	Market Sale (Disposal) 28th Feb 2022	64.94 %	₹ 238.12	2.26 lac	₹ 5.38 cr
Rajpal Singh Kochhar for and on behalf of Aresko Progressive Private Limited acting in capacity as a trustee of the Aresko Progressive Trust; and as the representative partner of J&P Investments Partnership Promoter Group	February-2022	Market Sale (Disposal) 25th Feb 2022	65.71 %	₹ 234.15	2.00 lac	₹ 4.68 cr
INDERPAL SINGH KOCHHAR Designated Person	January-2021	Market Purchase (Acquisition) 4th Jan 2021	0.21 %	₹ 72.06	17.64 k	₹ 12.71 lac

Corporate Actions

History of Jagsonpal Pharmaceuticals Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Dividend₹ 4/share
Record date: 4th Sep 2026Ex-date: 4th Sep 2026
Announced on: 27th Apr 2026
Others
Ex-date: 4th May 2026Announced on: 12th Mar 2026
"On Market Tender Offer."
Dividend₹ 2.50/share
Record date: 12th Sep 2025Ex-date: 12th Sep 2025
Announced on: 6th May 2025
Stock Split1 : 3
Ex-date: 8th Jan 2025Announced on: 23rd Oct 2024
Nominal Value change from INR 05 INR 02.
Dividend₹ 5/share
Record date: 6th Sep 2024Ex-date: 6th Sep 2024
Announced on: 20th May 2024

Company Profile

Overview of Jagsonpal Pharmaceuticals Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Jagsonpal Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is primarily engaged in the manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients (APIs). Its Gynaecology products include Divatrone, Endoreg, Cystelia-M, Fibristone, Yulipris...

Key personnel

Mr. Nirav Niranjankumar Vora

Chief Financial Officer

Mr. Amrut Medhekar

Chief Operating Officer

Mr. Pratham Rawal

Compliance Officer, Company Secretary

Mr. Rajpal Singh KochharD

Chairman Emeritus

Mr. Harsha RaghavanD

Non-Executive Chairman of the Board

Mr. Manish GuptaD

Managing Director, Director

Mr. Prithipal Singh KochharD

Non-Executive Director

Ms. Radhika Madhukar DudhatD

Non-Executive Independent Director

View all

Incorporated on

17 Aug 1978

Last Annual

31 Mar 2026

Last Interim

30 Jun 2026

No. of Employees

IPO date

13 Sep 1996

Free Float

1,57,64,528

Website

https://www.jagsonpal.com/

Phone no.

+911126494519

Address

Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar Sec-18, GURGAON, 122015, India

Frequently Asked Questions

What is the current share price of Jagsonpal Pharmaceuticals Ltd.?

The current share price of Jagsonpal Pharmaceuticals Ltd. is ₹ 230.65 as of 13 Aug 2026.

What is the market capitalisation of Jagsonpal Pharmaceuticals Ltd.?

The market capitalisation of Jagsonpal Pharmaceuticals Ltd. stands at ₹ 1,486.50 Cr.

What is the PE ratio of Jagsonpal Pharmaceuticals Ltd.?

The Price-to-Earnings (PE) ratio of Jagsonpal Pharmaceuticals Ltd. is 32.69 as of the latest trailing twelve months data.

What is the ROE and ROCE of Jagsonpal Pharmaceuticals Ltd.?

Jagsonpal Pharmaceuticals Ltd. has a Return on Equity (ROE) of 16.69% and a Return on Capital Employed (ROCE) of 18.23% as per the latest financial reports.

What is the 52-week high and low of Jagsonpal Pharmaceuticals Ltd.?

The 52-week high of Jagsonpal Pharmaceuticals Ltd. is - and the 52-week low is -.

What is the dividend yield of Jagsonpal Pharmaceuticals Ltd.?

The dividend yield of Jagsonpal Pharmaceuticals Ltd. is 1.77% based on the current market price.

What is the FII and DII holding in Jagsonpal Pharmaceuticals Ltd.?

Foreign Institutional Investors (FII) hold 2.30%, Domestic Institutional Investors (DII) hold 0.00% and retail/public investors hold 25.42% of Jagsonpal Pharmaceuticals Ltd. shares.

What sector does Jagsonpal Pharmaceuticals Ltd. belong to?

Jagsonpal Pharmaceuticals Ltd. operates in the Healthcare sector.

What is the beta of Jagsonpal Pharmaceuticals Ltd.?

The beta of Jagsonpal Pharmaceuticals Ltd. is 0.66, indicating its price volatility relative to the broader market. Over the past 1 year, Jagsonpal Pharmaceuticals Ltd. has delivered an absolute return of -17.73%.

What is the RSI of Jagsonpal Pharmaceuticals Ltd.?

The 14-day Relative Strength Index (RSI) of Jagsonpal Pharmaceuticals Ltd. is 46.74, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.

Jagsonpal Pharmaceuticals Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Jagsonpal Pharmaceuticals Ltd. Shareholding Pattern

Holdings and Presence

Bulk, Block and Insider Trades

Corporate Actions

Company Profile

Frequently Asked Questions

Company Profile

Corporate Actions

Stock Analysis

Holdings and Presence